Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Maze applied to be listed on the Nasdaq under the ticker symbol "MAZE," according to the filing. Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open' Proceeds ...

The shares are expected to begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol “MAZE.” The offering is expected to close on February 3, 2025, subject to the satisfaction of ...

Maze Therapeutics intends to list its shares on the Nasdaq Global Market under the ticker symbol "MAZE". J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are the lead underwriters ...